الفهرس 
Vascular Calcification in End Stage Renal Disease PatientsOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Background: Matrix Gla protein (MGP) acts as a potent local inhibitor of vascular calcification. However, to be active, MGP must be phosphorylated and carboxylated; such carboxylation is vitamin K-dependent, and phosphorylation is necessary for the secretion of MGP. This study aimed to investigated the effect of vitamin K2 on MGP levels after 3 months’ supplementation and the relationship between MGP level and vascular stiffness in hemodialysis patients.
Patients and methods: This interventional, double armed, clinical trial (Single-blinded) study was conducted in the dialysis Unit in Al-Ahrar Teaching Hospital, Sharkia on 48 end-stage renal disease (ESRD) patients on regular hemodialysis divided into 2 groups; 24 patients receiving Mk -7 as 90 mcg/day and 24 patients receiving placebo. Carotid duplex ultrasound for right and left common carotid arteries was done to assess Peak Wave Velocity (PWV) and the presence or absence of atheromatous plaques, prior to administering MK-7 and again after 3 months, for both groups.
Results: There was statistically nonsignificant difference between the studied groups regarding hemoglobin, serum calcium, phosphorus, potassium, sodium, alkaline phosphatase, Ktv and parathyroid hormone. There was statistically non-significant difference between the studied groups regarding baseline matrix Gla protein. There was statistically significant difference between the studied groups regarding matrix Gla protein after 3 months of administration of vitamin k2 supplementation and placebo within intervention and placebo groups respectively.
Conclusions: Vitamin k2 supplementation to hemodialysis patients will reduce ucMGP, which in turn reduces calcification and stiffness of blood vessels and cardiovascular system which in turn reduces cardiovascular morbidity and mortality.